Navigation Links
MGC Diagnostics Corporation Reports 2013 Second Quarter Operating Results

SAINT PAUL, Minn., May 30, 2013 /PRNewswire/ -- MGC Diagnostics Corporation (NASDAQ: MGCD) (formerly Angeion Corporation), a global medical technology company, today reported financial results for the second quarter ended April 30, 2013.


Second Quarter Highlights:

  • Robust second quarter revenue of $7.6 million, an increase of 35% over the fiscal 2012 second quarter. Sequential quarterly revenue growth of 8% from the first quarter of fiscal 2013;
  • Net income for the second quarter was $252,000, or $0.06 per diluted share, compared to a net loss of $409,000, or ($0.11) per diluted share in the 2012 second quarter;
  • Group Purchasing Organization ("GPO") sales increased 69% to $3.9 million, compared to $2.3 million in the 2012 second quarter;
  • Second quarter service revenue increased 8% on a year-over-year basis, while service gross margin improved to 70.3%, compared to 64.2% in the fiscal 2012 second quarter; 
  • Gross margin in the second quarter improved 210 basis points to 55.7%, compared to 53.6% in last year's second quarter;
  • The Attachment Rate of extended service contracts sold at the point of system sale improved to 27.4%, compared to 6.2% in last year's second quarter;
  • Second quarter 2013 recurring revenue (service and supplies revenues) totaled $2.6 million, or 35% of total second quarter revenue;
  • The Company declared and paid a special, one-time cash dividend of $0.45 per share during the quarter;
  • Strong balance sheet with $8.2 million in cash and cash equivalents, $12.4 million of working capital and no long-term debt after payment of the $1.8 million dividend;
  • At April 30, 2013, the Company had federal net operating loss carry forwards of approximately $14.5 million that may be used to offset a portion of the Company's future tax liability;
  • Rated #1 under a March 22, 2013 User Satisfaction Survey by MD Buyline, a provider of objective, evidence-based information used in the selection, acquisition, and management of medical technology;
  • Second quarter fiscal 2013 total revenues increased 35% to $7.6 million, compared to $5.6 million in the fiscal 2012 second quarter. Domestic 2013 second quarter sales increased 39% to $6.3 million, compared to $4.6 million in the 2012 second quarter, while international sales increased 18% to $1.3 million, from $1.0 million in last year's second quarter, due primarily to sales improvements in Canada and Latin America. Second quarter GPO sales increased 69% to $3.9 million, compared to $2.3 million in the prior year's second quarter. GPO sales accounted for approximately 51.2% of total sales for the second quarter, compared to 41.0% in the 2012 second quarter.

    Second quarter equipment, supplies and accessories sales totaled $6.4 million, an increase of 41.6%, compared to $4.5 million during last year's second quarter. Service revenues for the second quarter totaled $1.2 million, compared to $1.1 million during last year's second quarter. The Attachment Rate, which reflects the percentage of Extended Service Contracts added at the point of sale to customer equipment purchases, was 27.4% for the second quarter of fiscal 2013, compared to 6.2% for the same period last year. Backlog at April 30, 2013 was $541,000, which has steadily improved over the past six months from $530,000 at the end of the 2013 first quarter and $415,000 at the end of the 2012 fourth quarter, respectively.

    Gross margin for the quarter was 55.7%, compared to 53.6% in the 2012 second quarter.  Gross margin for equipment, supplies and accessories was 52.9% for the quarter, compared to 50.9% in the prior year's quarter. Gross margin for services increased to 70.3% for the quarter, compared to 64.2% for the prior year's quarter primarily as a result of improved pricing and service mix.

    Second quarter 2013 general and administrative expenses totaled $1.2 million, or 16.1% of revenue, compared to $930,000, or 16.6% of revenue in the comparable quarter last year. Sales and marketing expenses were $2.1 million, or 27.7% of revenue, compared to $1.7 million, or 29.5% of revenue in the 2012 second quarter. Research and development expenses were $640,000, or 8.5% of revenue, compared to $820,000, or 14.6% of revenue in last year's second quarter.  This decrease is due primarily to expense reductions attributed to the conversion of consultant services to full time, internal personnel.  Year to date, the Company has invested approximately $1 million in new research and product development initiatives.  Even though research and development expenses have decreased, the Company will continue to invest in new product development to ensure that its future product pipeline remains robust.

    Second quarter operating income improved to $258,000, compared to an operating loss of $509,000 in the 2012 second quarter. For the 2013 second quarter, the Company reported net income of $252,000, or $0.06 per diluted share, versus a net loss of $409,000, or ($0.11) per diluted share, in the 2012 second quarter.

    Gregg O. Lehman, Ph D., president and chief executive officer of MGC Diagnostics, said, "The positive financial results for the quarter represents the first time in several years since the Company has been profitable in its second fiscal quarter. We have achieved measureable progress on our key initiatives to reconfigure personnel, products and operating processes. The market has embraced our rebranding campaign, and our products are now well positioned and recognized as highly valuable solutions to deliver improved quality of care. We had solid growth across virtually all product categories and geographies, gross margins improved for all revenue sources and operating expenses as a percent of revenue fell to 52.3% compared to 62.6% for last year's second quarter. From our perspective, the results of this quarter are an important step towards achieving profitability for the full year."

    "For fiscal year 2013," continued Dr. Lehman, "we saw an opportunity to grow revenue by selling the quality of our products and capitalizing on the trust that customers have placed in our Company.  To that end, we set a goal to generate substantial new revenue from competitor accounts. For the first six months of the fiscal year, we have converted 39 new accounts from our competitors, representing approximately $2.6 million of new revenue.  I am pleased with the efforts of our sales, marketing and field service teams, all of whom do an outstanding job representing our products and services, and providing post-sale support to our customers. We are making good progress in accomplishing our goals for the fiscal year."

    "During the quarter, the Board authorized the payment of a special, one-time cash dividend to shareholders. After careful assessment by management and the Board, we determined that we had more than an appropriate level of capital to execute our strategic plan, as well as respond to contingencies and strategic opportunities. This determination presented an opportunity to reward our loyal shareholders with a special, one-time cash dividend. Of all that has been accomplished since I joined the company, I am particularly proud of the creativity, determination and dedication displayed by the entire MGC Diagnostics team to embrace the challenge of driving long-term growth and improving shareholder value," concluded Dr. Lehman.

    Discontinued Operations
    On August 28, 2012, the Company completed the sale of the assets of its New Leaf business to Life Time Fitness, Inc. for $1.235 million. As a result, the Company has reclassified its results for prior periods to eliminate from its statement of comprehensive income (loss) all fiscal 2012 revenues and expenses associated with its New Leaf business and presented the income from New Leaf activities as "discontinued operations."

    Net Operating Loss Carry Forward
    At April 30, 2013, the Company had federal net operating loss carry forwards of approximately $14.5 million, not subject to IRC annual limitations on use.  These loss carry forwards will expire in years 2018 through 2032.

    Conference Call
    The Company has scheduled a conference call for Thursday, May 30, 2013 at 4:30 p.m. ET to discuss its financial results for the second quarter of fiscal year 2013.

    Participants can dial (877) 317-6789 or (412) 317-6789 to access the conference call, or listen via a live Internet webcast on the Company's website at A replay of the conference call will be available by dialing (877) 344-7529 or (412) 317-0088, confirmation code 10029021, through June 6, 2013. A webcast replay of the conference call will be accessible on the Company's website at for 90 days.

    About MGC Diagnostics
    MGC Diagnostics Corporation (NASDAQ: MGCD), (formerly Angeion Corporation), is a global medical technology company dedicated to cardiorespiratory health solutions. The Company develops, manufactures and markets non-invasive diagnostic systems. This portfolio of products provides solutions for disease detection, integrated care, and wellness across the spectrum of cardiorespiratory healthcare. The Company's products are sold internationally through distributors and in the United States through a direct sales force targeting heart and lung specialists located in hospitals, university-based medical centers, medical clinics, physicians' offices, pharmaceutical companies, medical device manufacturers, and clinical research organizations (CROs). For more information about MGC Diagnostics, visit

    Cautionary Statement Regarding Forward Looking Statements
    From time to time, in reports filed with the Securities and Exchange Commission, in press releases, and in other communications to shareholders or the investing public, MGC Diagnostics Corporation may make forward-looking statements concerning possible or anticipated future financial performance, business activities or plans that include the words "believes," "expects," "anticipates," "intends" or similar expressions. For these forward-looking statements, the Company claims the protection of the safe harbor for forward-looking statements contained in federal securities laws.  These forward-looking statements are subject to a number of factors, risks and uncertainties, including those disclosed in our periodic filings with the SEC, that could cause actual performance, activities or plans after the date the statements are made to differ significantly from those indicated in the forward-looking statements. For a list of these factors¸ see the sections entitled "Risk Factors" and "Cautionary Note Regarding Forward Looking Statements," in the Company's Form 10-K for the year ended October 31, 2012, and any updates in subsequent filings on Form 10-Q or Form 8-K under the Securities Exchange Act of 1934.Contact:

    Wesley W. Winnekins

    Joe Dorame, Robert Blum, Joe DiazMGC Diagnostics Corporation

    Lytham Partners, LLCChief Financial Officer

    (602) 889-9700(651) 484-4874 Tables to Follow)

      MGC DIAGNOSTICS CORPORATION AND SUBSIDIARYConsolidated Balance Sheets(In thousands, except share and per share data) April 30,  October 31, 20132012Assets(Unaudited)Current Assets:Cash and cash equivalents$
    9,665Accounts receivable, net of allowance for doubtful accounts
    of $85 and $98, respectively6,3485,710Inventories, net of obsolescence reserve of $382 and $373, respectively4,0563,850Prepaid expenses and other current assets577568Total current assets19,14919,793Property and equipment, net of accumulated depreciation of $3,980
    and $3,876, respectively 785578Intangible assets, net1,9331,492Other non-current assets-85Total Assets$
    21,948Liabilities and Shareholders' EquityCurrent Liabilities:Accounts payable $
    2,094Employee compensation1,7911,749Deferred income2,2991,927Warranty reserve13591Other current liabilities and accrued expenses651442Total current liabilities6,7446,303Long-term liabilities:Long-term deferred income and other1,751895Total Liabilities8,4957,198Commitments and ContingenciesShareholders' Equity:Common stock, $0.10 par value, authorized 25,000,000 shares,
    4,083,129 and 3,986,350 shares issued and 3,998,690 and
    3,885,279 shares outstanding in 2013 and 2012, respectively400388Undesignated shares, authorized 5,000,000 shares, no shares issued
    and outstanding--Additional paid-in capital21,64321,046Accumulated deficit(8,671)(6,684)Total Shareholders' Equity13,37214,750Total Liabilities and Shareholders' Equity$   21,867$   21,948 


     MGC DIAGNOSTICS CORPORATION AND SUBSIDIARYConsolidated Statements of Comprehensive Income (Loss)(Unaudited in thousands, except per share amounts)

     Three Months Ended
    April 30,Six Months Ended
    April 30,2013201220132012RevenuesEquipment, supplies and accessories revenues$
    9,862Service revenues1,2031,1132,4052,1697,5635,60314,57112,031Cost of revenuesCost of equipment, supplies and accessories revenues2,9962,2045,8314,729Cost of service revenues3573987087323,3532,6026,5395,461Gross margin4,2103,0018,0326,570Operating expenses:Selling and marketing2,0941,6514,2203,426General and administrative1,2149302,6322,075Research and development6408201,2871,630Amortization of intangibles4109112173,9523,5108,1507,348Operating income (loss)258(509)(118)(778)Interest income1-14Income (loss) from continuing operations before taxes259(509)(117)(774)Provision for taxes771414Income (loss) from continuing operations252(516)(131)(788)Discontinued operationsIncome from discontinued operations-107-130Net income (loss)252(409)(131)(658)Other comprehensive loss; net of taxUnrealized loss on securities-(1)-(2)Comprehensive income (loss)$
    (660)Income (loss) per shareBasicFrom continuing operations$
    (0.21)From discontinued operations0.$
    (0.17)DilutedFrom continuing operations$
    (0.21)From discontinued operations0.$
    (0.17)Weighted average common shares outstandingBasic3,9303,7973,9103,789Diluted3,9943,7973,9103,789Dividends declared per share$


     MGC DIAGNOSTICS CORPORATION AND SUBSIDIARYConsolidated Statements of Cash Flows(Unaudited in thousands)Six Months Ended
    April 30,20132012Cash flows from operating activities:Net loss$
    (658)Adjustments to reconcile net loss to net cash provided by operating activities:Depreciation110126Amortization53217Stock-based compensation234183Decrease in allowance for doubtful accounts(13)(64)Increase in inventory obsolescence reserve957Gain on disposal of equipment(3)-Changes in operating assets and liabilities:Accounts receivable(625)1,945Inventories(215)(703)Prepaid expenses and other current assets76(89)Accounts payable(226)(395)Employee compensation42(79)Deferred income1,058(98)Warranty reserve44(40)Other current liabilities and accrued expenses98182Net cash provided by operating activities511584Cash flows from investing activities:Sales of investments-241Purchases of property and equipment and intangible assets(598)(505)Net cash used in investing activities(598)(264)Cash flows from financing activities:Dividends paid(1,800)-Proceeds from issuance of common stock under employee stock purchase plan6811Proceeds from the exercise of stock options34540Repurchase of common stock-(10)Repurchase of common stock upon vesting of restricted stock awards(23)-Net cash (used in) provided by financing activities(1,410)41Net (decrease) increase in cash and cash equivalents(1,497)361Cash and cash equivalents at beginning of period9,6658,461Cash and cash equivalents at end of period$
    8,822Cash paid for taxes$
    3Supplemental non-cash items:Current and non-current liabilities issued for leasehold improvements$
    -Accrued dividends56- 


    SOURCE MGC Diagnostics Corporation
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Apnix Sleep Diagnostics Announces New Houston Sleep Apnea Treatments
    2. Alzheimer Market: Drugs, Therapeutics & Diagnostics Research Reports
    3. MGC Diagnostics Corporation to Report Second Quarter Fiscal 2013 Financial Results on Thursday, May 30, 2013
    4. Exosome Diagnostics Presents Data Demonstrating Utility of Urine Exosome Technology to Predict Prostate Biopsy Outcome at American Urological Association Annual Meeting
    5. Algeta and Lumiphore Announce Further Expansion of Their Global Partnership for the Development of Targeted Alpha-pharmaceutical Cancer Therapeutics and Companion Diagnostics.
    6. BD Diagnostics Advances Commitment to a Fully Integrated Microbiology Solution with New Agreement
    7. Apnix Sleep Diagnostics Offering New Home Sleep Study Materials
    8. LamdaGen Corporation Issued United States Patent for Diagnostics on Plasmonic-Based Nanosensors
    9. Nipro Diagnostics Leverages Managed IT Services from JDL Technologies to Support Growth and Technological Innovation
    10. 2013 Cancer Diagnostics Market Analysis: Cancer Testing Industry Growing Rapidly
    11. Quest Diagnostics Reports First Quarter 2013 Financial Results
    Post Your Comments:
    (Date:11/26/2015)... November 26, 2015 ... addition of the  "2016 Future Horizons ... Therapeutic Drug Monitoring (TDM) Market: Supplier ... Emerging Opportunities"  report to their offering.  ... announced the addition of the  "2016 ...
    (Date:11/26/2015)... 2015 ) ... "Radioimmunoassay Market by Type (Reagents & Kits, ... Clinical Diagnostic Labs), Application (Research, Clinical Diagnostics), ... report to their offering. --> ... of the "Radioimmunoassay Market by Type ...
    (Date:11/25/2015)... THOUSAND OAKS, Calif. , Nov. 25, 2015 /PRNewswire/ ... of a Biologics License Application (BLA) with ... Administration (FDA) for ABP 501, a biosimilar candidate to ... the first adalimumab biosimilar application submitted to the FDA ... biosimilar pathway. Sean E. Harper , M.D., ...
    Breaking Medicine Technology:
    (Date:11/25/2015)... ... November 25, 2015 , ... ... aggressive than those found on mammography, according to a study published online in ... cancers not seen on mammography may necessitate a change in treatment. , Breast ...
    (Date:11/25/2015)... , ... November 25, 2015 , ... ... offering factory direct sauna parts and accessories. , Sauna accessories help improve the ... bather’s style and personality. From basic styles for the purist looking for simplicity ...
    (Date:11/25/2015)... ... November 25, 2015 , ... According to an article ... being more and more widely heralded as a breakthrough for performing hernia repairs. The ... over traditional laparoscopic surgery is that it can greatly reduce the pain that a ...
    (Date:11/25/2015)... ... 25, 2015 , ... The McHenry County law firm of Botto Gilbert ... Attorneys Francisco J. Botto and Alex C. Wimmer. Attorneys Botto and Wimmer represented the ... App (2d) 130884WC. , According to court documents, Adcock testified that on May 10, ...
    (Date:11/25/2015)... , ... November 25, 2015 , ... ... decades of music, friendships, and learning in its 65th Anniversary Brillianteen Revue, scheduled ... 5-6. , For 65 years, Brillianteen has been a treasured tradition ...
    Breaking Medicine News(10 mins):